SCHEMBL12436759

SCHEMBL12436759

CCOC(=O)NC1CCC(C(C)=O)CC1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
GAA P10253 2/20 0.44
EPHX1 P07099 2/20 0.44
TSHR P16473 1/20 0.42
DRD2 P14416 1/20 0.41
SMYD3 Q9H7B4 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
HSD11B1 P28845 1/20 0.40
RECQL P46063 1/20 0.39
EPHX2 P34913 1/20 0.39
KDM4E B2RXH2 1/20 0.39
HTT P42858 2/20 0.37
CASP6 P55212 1/20 0.37
MAPK1 P28482 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22722028 1.00 ALDH1A1 (0.44) ALDH1A1GAAEPHX1TSHRDRD2
SCHEMBL18380884 0.89 SMYD3 (0.47) ALDH1A1GAAEPHX1TSHRDRD2
SCHEMBL7788916 0.89 SMYD3 (0.47) ALDH1A1GAAEPHX1TSHRDRD2
SCHEMBL7470486 0.89
Hydrochloric Acid SCHEMBL3971132 0.87 SMYD3 (0.46) ALDH1A1GAAEPHX1TSHRDRD2
SCHEMBL12513735 0.85 EPHX1 (0.46) ALDH1A1GAAEPHX1DRD2SMYD3
SCHEMBL22722037 0.85 EPHX1 (0.46) ALDH1A1GAAEPHX1DRD2SMYD3
SCHEMBL6483370 0.81 EPHX2 (0.52) ALDH1A1GAAEPHX1TSHRDRD2
SCHEMBL15906231 0.81 EPHX1 (0.48) ALDH1A1GAAEPHX1TSHRDRD2
SCHEMBL5949999 0.81 EPHX1 (0.48) ALDH1A1GAAEPHX1TSHRDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49686-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-10 US disclosed
US-RE48334-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-12-01 US disclosed
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME NTSR2, BDKRB1, AVPR1B ALDH1A1 3648/4885GAA 4829/4885EPHX1 3088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.